L
21.75
0.47 (2.21%)
| 前收盘价格 | 21.28 |
| 收盘价格 | 21.45 |
| 成交量 | 622,994 |
| 平均成交量 (3个月) | 1,787,431 |
| 市值 | 4,016,998,144 |
| 预期市盈率 (P/E Forward) | 70.42 |
| 价格/销量 (P/S) | 4.83 |
| 股市价格/股市净资产 (P/B) | 4.36 |
| 52周波幅 |
| 营业毛利率 | -29.95% |
| 营业利益率 (TTM) | -25.97% |
| 稀释每股收益 (EPS TTM) | -1.18 |
| 季度收入增长率 (YOY) | 107.50% |
| 总债务/股东权益 (D/E MRQ) | 35.65% |
| 流动比率 (MRQ) | 5.20 |
| 营业现金流 (OCF TTM) | -263.30 M |
| 杠杆自由现金流 (LFCF TTM) | -202.32 M |
| 资产报酬率 (ROA TTM) | -8.77% |
| 股东权益报酬率 (ROE TTM) | -20.00% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Legend Biotech Corporation | 看跌 | 看跌 |
AIStockmoo 评分
0.3
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.25 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 1.31% |
| 机构持股比例 | 47.92% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Hhlr Advisors, Ltd. | 30 Sep 2025 | 5,984,550 |
| Suvretta Capital Management, Llc | 30 Sep 2025 | 3,818,009 |
| Braidwell Lp | 30 Sep 2025 | 1,826,155 |
| Matthews International Capital Management Llc | 30 Sep 2025 | 1,028,447 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 90.00 (Barclays, 313.79%) | 购买 |
| 中 | 74.00 (240.23%) | |
| 低 | 48.00 (UBS, 120.69%) | 购买 |
| 平均值 | 67.43 (210.02%) | |
| 总计 | 7 购买 | |
| 平均价格@调整类型 | 28.01 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Cantor Fitzgerald | 17 Dec 2025 | 74.00 (240.23%) | 购买 | 21.42 |
| 13 Nov 2025 | 75.00 (244.83%) | 购买 | 31.01 | |
| Morgan Stanley | 12 Dec 2025 | 50.00 (129.89%) | 购买 | 22.32 |
| UBS | 08 Dec 2025 | 48.00 (120.69%) | 购买 | 26.12 |
| Barclays | 13 Nov 2025 | 90.00 (313.79%) | 购买 | 31.01 |
| RBC Capital | 13 Nov 2025 | 74.00 (240.23%) | 购买 | 31.01 |
| HC Wainwright & Co. | 17 Oct 2025 | 60.00 (175.86%) | 购买 | 31.96 |
| JP Morgan | 09 Oct 2025 | 76.00 (249.43%) | 购买 | 32.22 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合